{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-26-000098","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-08-04T20:05:45+00:00","discovered_at":"2026-08-04T20:07:00.223737+00:00","generated_at":"2026-08-04T20:07:41.723464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre reports Q2 net loss $36.2M; cash $1.15B; positive Phase 2 data for SPY001/SPY002 in UC","bullets":["Net loss of $36.2M in Q2 2026 vs $36.7M in Q2 2025; R&D expenses rose to $65.5M from $40.1M.","Cash, equivalents, and marketable securities of $1,145.3M as of June 30, 2026; raised $435.2M net in April 2026 public offering.","SPY001 achieved 40% clinical remission and 51% endoscopic improvement; SPY002 achieved 33% and 42%, respectively, in Part A of SKYLINE UC trial.","Enrollment completed for Phase 2 SKYWAY basket trial in RA, PsA, axSpA; RA data expected September 2026, PsA/axSpA data in Q4 2026.","Recognized $40.0M gain on milestone from sale of priority review voucher related to legacy asset pegzilarginase."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000098","json":"https://secwatch.observer/filing/0001636282-26-000098.json","markdown":"https://secwatch.observer/filing/0001636282-26-000098.md","text":"https://secwatch.observer/filing/0001636282-26-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/0001636282-26-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/syre-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:07:41.723464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}